BMS Archive

Plant · Scientific monograph

Mentha × piperita

Peppermint

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Digestive health, Gastrointestinal motility

Research overview

Historical use

Peppermint oil has a documented European history of digestive use; traditional cough, muscle-pain and itching applications have a separate evidence basis from oral IBS research [5].

Modern research context

Enteric-coated peppermint oil has been studied for IBS symptoms, with inconsistent trial results [1][2]. A 2022 synthesis of 10 RCTs (1030 participants) reported pooled symptom benefit but rated certainty very low and found more adverse events [1]. A 6-week trial in people with Rome IV IBS found no superiority over placebo [2]. A 2026 trial in children aged 8–18 years likewise found neither peppermint oil nor peppermint sweets superior to placebo after eight weeks [6]. BMS Level U for a firm general efficacy conclusion; formulation-specific human research exists. Pediatric PK studies describe exposure, not established pediatric treatment regimens [3][4].

Adverse effects

Heartburn, nausea and perianal burning are reported; reflux can worsen, including in people with hiatal hernia. Allergy can occur. Trial adverse events were more frequent than placebo in the synthesis [1][5].

Contraindications

EMA lists oil/menthol hypersensitivity, liver disease, cholangitis, gallstones, other biliary disorders and achlorhydria for oral gastro-resistant preparations. Oral IBS preparations are not recommended below age 8; other routes have distinct age restrictions, including contraindication below age 2 [5]. Worsening symptoms warrant medical advice [5]. EMA also contraindicates its traditional-use preparations in children with a seizure history; age limits vary by route [5].

Clinical and phytochemical data

Used part

Peppermint essential oil; clinical evidence here concerns enteric-coated oil, not leaf tea [2][5].

Primary active compounds

  • Menthol (monoterpene; studied PK marker) [3][4]

  • Essential-oil terpenes; product composition varies [5]

Mechanism of action

EMA describes gastrointestinal smooth-muscle spasmolysis in human pharmacological studies. This does not establish symptom benefit in every IBS population or identify a single clinically validated molecular target [5].

Pharmacokinetics

Absorption

Human studies measured systemic menthol after enteric-coated oil; exposure depends on dose/formulation. In a small pediatric study peak concentration occurred about 2.5 hours after dosing [4].

Distribution

Human whole-oil tissue distribution is insufficiently characterized in the retrieved sources; pediatric PK findings do not establish adult distribution [3][4].

Metabolism

EMA describes glucuronide formation and limited clinical observations of CYP3A4 inhibition; interaction magnitude remains incompletely defined [5].

Excretion

Menthol glucuronide elimination is described in EMA; modified release delays urinary excretion relative to immediate release. No universal whole-oil half-life is established here [5].

Safety and interactions

Drug interactions

Antacids, H2 blockers and proton-pump inhibitors may cause premature dissolution of gastro-resistant coatings. Limited CYP3A4 observations do not establish a quantified interaction with every substrate [5].

Toxicity

Concentrated oil overdose can cause serious neurologic and cardiac effects. Animal high-dose pulegone/menthofuran findings are not direct estimates of clinical cancer risk [5].

Special precautions

Pregnancy

Medicinal-oil pregnancy safety is unestablished; EMA does not recommend use with insufficient data [5].

Lactation

EMA does not recommend medicinal use; milk transfer is unknown [5].

Hepatic impairment

Oral gastro-resistant oil is contraindicated in liver disease in the EMA monograph [5].

Renal impairment

No validated renal dose adjustment identified; renal-impairment PK and safety remain gaps in this extraction [3][4][5].

Sources and references

  1. [1] - Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Alimentary pharmacology & therapeutics 2022. PMID: 35942669. DOI: 10.1111/apt.17179.
  2. [2] - Nee J, Ballou S, Kelley JM, Kaptchuk TJ, Hirsch W, Katon J, Cheng V, Rangan V, Lembo A, Iturrino J. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. The American journal of gastroenterology 2021. PMID: 34319275. DOI: 10.14309/ajg.0000000000001395.
  3. [3] - Shulman RJ, Chumpitazi BP, Abdel-Rahman SM, Garg U, Musaad S, Kearns GL. Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain. British journal of clinical pharmacology 2022. PMID: 34528282. DOI: 10.1111/bcp.15076.
  4. [4] - Shulman RJ, Chumpitazi BP, Gonzalez D, Garg U, Musaad S, Wen J, Kearns GL. Randomized trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain: 540 mg vs. 900 mg dose comparison. British journal of clinical pharmacology 2025. PMID: 40390282. DOI: 10.1002/bcp.70097.
  5. [5] - EMA/HMPC. Official herbal monograph, full regulatory text, sections 4.3–5.3. https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf Accessed 2026-10-25.
  6. [6] - Vermeijden NK et al. Peppermint Oil and Sweets in Pediatric Irritable Bowel Syndrome and Functional Abdominal Pain: A Randomized Trial. Clinical Gastroenterology and Hepatology 2026;24:2286–2296. PMID: 41610933. DOI: 10.1016/j.cgh.2026.01.014. Abstract reviewed; full-text appraisal pending.

Additional source links

Continue browsing